Cue Biopharma (CUE) Competitors $0.76 -0.01 (-1.24%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CUE vs. MDWD, RZLT, CRDF, IVA, FULC, BTMD, SOPH, GOSS, ANNX, and HURAShould you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include MediWound (MDWD), Rezolute (RZLT), Cardiff Oncology (CRDF), Inventiva (IVA), Fulcrum Therapeutics (FULC), biote (BTMD), SOPHiA GENETICS (SOPH), Gossamer Bio (GOSS), Annexon (ANNX), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry. Cue Biopharma vs. MediWound Rezolute Cardiff Oncology Inventiva Fulcrum Therapeutics biote SOPHiA GENETICS Gossamer Bio Annexon TuHURA Biosciences Cue Biopharma (NASDAQ:CUE) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, community ranking, profitability, media sentiment, analyst recommendations, risk and institutional ownership. Which has stronger valuation and earnings, CUE or MDWD? MediWound has higher revenue and earnings than Cue Biopharma. MediWound is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCue Biopharma$9.29M5.03-$50.73M-$0.75-1.01MediWound$20.22M9.46-$6.72M-$3.07-5.77 Does the media refer more to CUE or MDWD? In the previous week, MediWound had 2 more articles in the media than Cue Biopharma. MarketBeat recorded 3 mentions for MediWound and 1 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 1.16 beat MediWound's score of 0.63 indicating that Cue Biopharma is being referred to more favorably in the media. Company Overall Sentiment Cue Biopharma Positive MediWound Positive Does the MarketBeat Community believe in CUE or MDWD? MediWound received 251 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 62.23% of users gave MediWound an outperform vote while only 52.33% of users gave Cue Biopharma an outperform vote. CompanyUnderperformOutperformCue BiopharmaOutperform Votes14652.33% Underperform Votes13347.67% MediWoundOutperform Votes39762.23% Underperform Votes24137.77% Is CUE or MDWD more profitable? MediWound has a net margin of -142.29% compared to Cue Biopharma's net margin of -468.02%. MediWound's return on equity of -82.17% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cue Biopharma-468.02% -156.38% -88.07% MediWound -142.29%-82.17%-33.67% Do institutionals and insiders hold more shares of CUE or MDWD? 35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 12.3% of Cue Biopharma shares are held by company insiders. Comparatively, 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer CUE or MDWD? Cue Biopharma currently has a consensus price target of $3.00, indicating a potential upside of 297.30%. MediWound has a consensus price target of $31.33, indicating a potential upside of 77.02%. Given Cue Biopharma's higher probable upside, research analysts clearly believe Cue Biopharma is more favorable than MediWound.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00MediWound 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, CUE or MDWD? Cue Biopharma has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. SummaryMediWound beats Cue Biopharma on 10 of the 16 factors compared between the two stocks. Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUE vs. The Competition Export to ExcelMetricCue BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.68M$6.90B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-0.847.4522.4218.48Price / Sales5.03242.72394.10103.91Price / CashN/A65.8538.1834.62Price / Book0.926.516.774.25Net Income-$50.73M$143.21M$3.22B$248.23M7 Day Performance-9.71%3.97%3.26%3.29%1 Month Performance-17.92%0.37%0.02%2.42%1 Year Performance-60.26%2.60%18.01%5.54% Cue Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CUECue Biopharma4.2229 of 5 stars$0.76-1.2%$3.00+297.3%-60.3%$46.68M$9.29M-0.8460Upcoming EarningsPositive NewsMDWDMediWound1.4405 of 5 stars$17.65+3.2%$31.33+77.5%-4.9%$190.76M$20.22M-6.0980RZLTRezolute2.6886 of 5 stars$3.14+14.2%$26.43+741.7%+40.3%$190.08MN/A-2.5740Analyst ForecastShort Interest ↑High Trading VolumeCRDFCardiff Oncology1.4324 of 5 stars$2.82-1.1%$11.67+313.7%-37.2%$187.60M$683,000.00-3.0020IVAInventiva1.9363 of 5 stars$3.56+6.0%$10.40+192.1%+17.1%$186.82M$9.20M0.00100Gap DownFULCFulcrum Therapeutics1.9771 of 5 stars$3.46+5.2%$8.63+149.3%-46.0%$186.77M$80M-11.16100News CoveragePositive NewsBTMDbiote3.732 of 5 stars$3.41+3.3%$8.00+134.6%-39.6%$186.56M$197.19M13.12194Upcoming EarningsPositive NewsSOPHSOPHiA GENETICS2.3684 of 5 stars$2.78-1.8%$6.80+144.6%-40.2%$185.39M$65.17M-2.55520Upcoming EarningsNews CoverageGOSSGossamer Bio3.9747 of 5 stars$0.81-3.5%$7.50+822.5%+43.7%$184.73M$114.70M-2.54180Upcoming EarningsNews CoveragePositive NewsANNXAnnexon2.031 of 5 stars$1.68+15.1%$18.67+1,011.1%-59.1%$184.31MN/A-1.6060Positive NewsGap DownHURATuHURA BiosciencesN/A$4.20+1.2%$12.67+201.6%N/A$183.46MN/A0.00N/ANews CoveragePositive News Related Companies and Tools Related Companies MediWound Alternatives Rezolute Alternatives Cardiff Oncology Alternatives Inventiva Alternatives Fulcrum Therapeutics Alternatives biote Alternatives SOPHiA GENETICS Alternatives Gossamer Bio Alternatives Annexon Alternatives TuHURA Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUE) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CUE Stock Free CUE Stock Alerts